https://www.yna.co.kr/view/AKR20261002105851017

Channel
제약/바이오/미용 원리버 Oneriver
@pharmbiohana
On this record: Topic · Growth · Engagement · What this channel posts · Reactions · Stars · Posts · Polls · Citations · Telegram's recommendations · Cite this entry
29,812subscribers
+1 since we began measuring on 6 August 2026
Risers and fallers across the register · movement among entries of 10,000–31,623.
Register entry
| Telegram ID | -1001544338145 |
|---|---|
| Type | Channel |
| Username | @pharmbiohana |
| Description | 인생에 도움이 되는 바이오 영상 모음집 https://youtube.com/@Iamoneriver 바이오 시그널 랩에서 원리버와 함께하기 https://fanding.kr/@iamoneriver/membership/plan/9099/ 문의 [email protected] 해당 채널의 게시물은 단순 의견 및 기록용도이고 매수-매도 등 투자권유를 의미하지 않습니다. 해당 게시물의 내용은 부정확할 수 있으며 매매에 따른 손실은 거래 당사자의 책임입 |
| Created | 7 November 2021 — measured — cross-checked against a third-party dataset (ext.tg_channel) |
| First recorded | 6 August 2026 |
| Last confirmed live | 26 September 2026 |
| Measurements held | 33 |
| Confirmed unchanged | 1 time, most recently 26 September 2026 |
| On Telegram | t.me/pharmbiohana |
Topic
Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 9 September 2026 and assigned it the closest of 31 fixed categories, at 67% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.
Growth
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 26 Sept 2026, 08:19 | 29,812 | -31 |
| 19 Sept 2026, 08:41 | 29,843 | -27 |
| 16 Sept 2026, 23:39 | 29,870 | -15 |
| 13 Sept 2026, 15:18 | 29,885 | -8 |
| 11 Sept 2026, 18:42 | 29,893 | -21 |
| 9 Sept 2026, 07:39 | 29,914 | -26 |
| 5 Sept 2026, 23:42 | 29,940 | -1 |
| 3 Sept 2026, 19:58 | 29,941 | -14 |
| 2 Sept 2026, 10:44 | 29,955 | +2 |
| 1 Sept 2026, 08:36 | 29,953 | -10 |
| 31 Aug 2026, 05:44 | 29,963 | -8 |
| 30 Aug 2026, 02:58 | 29,971 | -9 |
| 29 Aug 2026, 04:07 | 29,980 | +1 |
| 28 Aug 2026, 03:34 | 29,979 | -12 |
| 27 Aug 2026, 03:44 | 29,991 | -4 |
| 26 Aug 2026, 00:35 | 29,995 | -6 |
| 25 Aug 2026, 01:52 | 30,001 | -8 |
| 23 Aug 2026, 17:47 | 30,009 | +8 |
| 22 Aug 2026, 04:48 | 30,001 | +9 |
| 21 Aug 2026, 00:07 | 29,992 | first reading |
Engagement
449 posts held, back to 5 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 84 pages of Telegram’s post history, 20 posts per page.
- ERR · 30 days
- 16.5%
- avg views ÷ 29,812 subscribers
- Avg views / post
- 4,910
- 143 posts measured
- Reaction rate
- 0.307%
- reactions ÷ views · ER floor
- Posts in window
- 146
- of 449 held
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate. It is computed over the 133 of 143 measured posts that carry a reaction reading, and over those same posts' views.
| Window | Rolling 30 days · latest post in window 2 October 2026 |
|---|---|
| Posts held | 449 (5 August 2026 – 2 October 2026) |
| Views total | 702,770 |
| Reactions total | 2,023 |
| Forwards / comments | not exposed by the public surface — not measured, not estimated |
| Readings taken | 2 Oct 2026, 09:46 UTC |
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
What this channel posts
- Photos
- ≈1,780
- Videos
- ≈10
- Links
- ≈6,870
Lifetime counters from Telegram’s own channel header, read 2 October 2026 — not the date at the top of this page, which is when the subscriber count was last read. A count marked ≈ was rounded by Telegram before we ever saw it — t.me prints these counters in full below 1,000 and to three significant figures above, so ≈142,000 means somewhere between 141,500 and 142,499.
Reaction mix
8,380 reactions across 421 posts, in 12 distinct kinds. The most used accounts for 41.8% of them.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| ❤ | 3,505 | 41.8% | |
| 👍 | 1,880 | 22.4% | |
| 🤯 | 1,517 | 18.1% | |
| 😱 | 704 | 8.40% | |
| 💊 | 174 | 2.08% | |
| 👌 | 166 | 1.98% | |
| 🥰 | 134 | 1.60% | |
| 🤩 | 101 | 1.21% | |
| 😍 | 78 | 0.931% | |
| 🕊 | 56 | 0.668% | |
| ✍ | 38 | 0.453% | |
| ❤🔥 | 27 | 0.322% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 426 of the 449 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 8,380 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 449 most recent posts we hold, published 5 August 2026 to 2 October 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
Telegram Stars
- Stars received
- 102
- across the posts below
- Posts paid on
- 3
- of 441 we hold a reading for · 0.7%
- Most on one post
- 100
- single highest reading
A paid reaction is a reader spending Telegram Stars — bought with money — on a post by @pharmbiohana. Telegram publishes the count on the public post preview alongside ordinary reactions, and this register reads it there. It is the only figure on this site that measures money moving rather than attention.
Stars are not reactions, and the two are never added. They are rendered in the same strip on Telegram and counted in the same shape, but one is a tap and the other is a purchase. The reaction totals and the engagement rate elsewhere on this page exclude every figure in this section, and no rate here is computed against a reaction count.
This is not revenue, and we publish no currency figure. What a Star costs a reader and what it pays a channel are different numbers, Telegram takes a share we cannot observe, and the terms have changed. Converting a Star count into money would be an estimate dressed as a measurement, so the count is where we stop.
Counted over the 449 most recent posts we hold for this entry, published 5 August 2026 to 2 October 2026. Star counts above 1,000 reach us in Telegram’s short form and carry the same three-significant-figure rounding as everything else on this page.
Recent posts
[단독] SK바이오팜, 차세대 항암제 'KRAS G12D' 신약 개발 중단...RPT 집중 차세대 항암제로 키우던 'KRAS G12D' 세계 3대 암 학회서 동물실험 성과까지 공개했지만 글로벌 경쟁 심화 속 우선순위 조정 개발 잠정 중단 방사성의약품 중심으로 항암제 포트폴리오 재편 https://biz.chosun.com/science-chosun/bio/2026/10/02/SKTGSQYGNFG2BMYH6GJUVJQCLU/
👍5❤1
사노피, 듀피젠트 다음 세대 준비…리제네론에 최대 80억달러 이번 계약은 업프론트 10억 달러 + 개발·허가·상업화 마일스톤 최대 70억 달러, 총 최대 80억 달러 규모입니다. 양사는 신규 파이프라인의 개발·상업화 비용과 향후 이익도 50:50으로 나눕니다. -> 듀피젠트 이후의 차세대 장기지속형 면역질환 파이프라인 확보입니다. 이번에 추가되는 자산은 - 장기지속형 IL-13 항체 REGN20423 — 현재 아토피피부염 1상 - 장기지속형 IL-4 × IL-13 이중항체 - IL-4 표적 장기지속형 항체 - IL-4Rα 표적 장기지속형 항체 총 4개 프로그램으로, 나머지 3개는 2027년 임상 진입 예정입니다. 결국 사노피와 리제네론이 듀피젠트로 검증한 Type 2 inflammation 영역을 그대로 확장하면서, 투여 주기를 늘린…
❤16🤯3
Evommune이 EADV 2026에서 아토피피부염 대상 EVO301 2a 임상 PoC 데이터를 발표 #에보뮨 - IL-18 억제 기전의 장기지속형 주사제 - 중등도~중증 AD 환자 70명 대상, 5mg/kg IV를 0주·4주 2회 투여 - 12주차 EASI 평균 55% 감소 vs 위약 22%, 1차 평가지표 충족(p<0.01) - EASI-50: 63% vs 23%, EASI-75: 29% vs 9% - 마지막 투여 후 8주가 지난 12주차까지 효과가 계속 개선되며 지속성 확인 - Th2뿐 아니라 Th1, Th17/22까지 광범위한 염증 경로 억제 확인 - 안전성은 위약과 유사했고 중대한 치료 관련 이상반응이나 중단 사례는 없었음 - PK상 4주 간격 투여 및 유지요법에서 8~12주 간격 가능성 제시 - 피하주사 제형 기반 2b 용량탐색 …
❤15
https://www.mk.co.kr/news/stock/12166522?sicode=01
❤6
2026.10.01 17:23:43 기업명: 삼성에피스홀딩스(시가총액: 9조 1,570억) A0126Z0 보고서명: 투자판단관련주요경영사항(자회사의 주요경영사항) (중증 호산구 천식 치료제 SB41(Fasenra 바이오시밀러) 및 유전성 재발열 증후군 치료제 SB44(Ilaris 바이오시밀러) 파트너십 계약 체결) 종속회사 : 삼성바이오에피스 제목 : 중증 호산구 천식 치료제 SB41(Fasenra 바이오시밀러) 및 유전성 재발열 증후군 치료제 SB44(Ilaris 바이오시밀러) 파트너십 계약 체결 * 주요내용 ※ 투자유의사항 동 계약은 조건부 계약으로 본 계약을 통한 수익 인식은 임상시험과 품목허가 등의 성공 여부에 따라 달라질 수 있습니다. 계약 조건에 따라, 규제기관에 의한 연구 개발의 중단, 품목허가 실패…
❤7👍1
HLB제약(047920) 신규시설투자등 투자금액 : 550 억원 자본대비(%) : 43.95 투자 목적 : 생산능력 확대, 노후 생산설비 개선 및 안정적인 생산기반 확보 시작일 : 2026-10-01 종료일 : 2028-01-31 http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261001900652
😱3
ㄴ국장 마감 직후부터 나스닥 선물이 급락 중입니다. 동시에 미국채 10년물 금리가 5.360(0.92%) 급등합니다. 유가도 브렌트유와 WTI가 약 2% 가량 상승하고 있습니다. 중동 쪽은 예멘 정규군이 후티 반군의 진지를 공격했다는 뉴스와 이란 혁수대가 테헤란 인근에서 테러단체 소속원 6명을 사살했다는 뉴스가 있습니다. 추가로 좀 더 체크해보겠습니다.
👍12😱5❤4
코스닥 조롱은 역시 바닥이구나...
👍27❤12😱10🤯8🕊6
#KODEX코스닥150레버리지 VI
❤11
안녕하십니까, 아이엠바이오로직스 IR팀입니다. 당사가 개발해 기술이전한 IMB-101(NAV-240)의 글로벌 파트너사인 미국 네비게이터 메디신(Navigator Medicines)이 보도자료를 배포했습니다. 유럽피부과학회(EADV 2026)에서 NAV-240 및 차세대 약물 NAV-242의 신규 임상·전임상 데이터를 발표하고 개발 현황을 공개한다는 내용으로, 주요 사항을 요약해 드립니다. ■ 주요 학회 발표 내용 및 개발 현황 ① NAV-240 임상 2a상(MAINSAIL) 진행 순항 중등도~중증 화농성 한선염(HS) 환자 대상 2a상 환자 모집이 예정보다 빠르게 진행 중 (결과는 2027년 3분기 예정) ② NAV-240 임상 1상 결과 발표 (포스터 P1749) 건강한 자원자 64명 반복 투여 결과, 수용 가능한 안전성·내약성…
❤2
바닥에서 반등하고 있는 토모뿐 아니라 다른 굿 바이오도 보러오세요 👍🏻
❤22👌4🤯4
Showing the 12 most recent of 449 posts we hold for @pharmbiohana. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Polls
The poll we hold for this entry, as Telegram rendered it when we read the post. A poll’s figures keep moving after that, so each one is dated.
‘전닉 랠리 시즌2 or 시체 줍줍 코스닥 시즌1‘
- 죽어도 전닉41%
- 코스닥 1000pt59%
Shares as published. No per-option vote count is published by Telegram, so none is shown.
Percentages only — there are no per-option vote counts here, because Telegram publishes none. The public post preview gives each option’s share and a single voter total, and nothing else. Multiplying one by the other would produce a per-option tally that looks measured and is not: the shares are rounded to whole numbers before we ever see them. We print what was published and leave the column that does not exist empty.
The shares need not add up to 100. Rounding alone puts many polls at 99 or 101. A poll that allows more than one answer per voter runs well past 100 by design, and several here do. The bars are drawn against a fixed 100% track at each option’s own percentage rather than normalised to the total, so a poll that exceeds it shows that it does instead of being quietly rescaled.
Read from the 449 most recent posts we hold, published 5 August 2026 to 2 October 2026. Telegram labels each poll by kind — an anonymous poll, a quiz, a closed set of final results — and that label is reproduced rather than paraphrased.
Forward network
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
@bbanjil · 10,7324 posts글로벌바이오아저씨
@choaz1 · 7,0684 posts급등일보 미국주식🇺🇸 속보·매크로·리서치
@FastStockNewsUSA · 40,6783 postsYeouido Lab_여의도 톺아보기
@Yeouido_Lab · 43,2773 posts간절한 투자스터디카페
@desperatestudycafe · 18,7513 posts호그니엘
@hogniel · 15,3153 posts텐렙
@Ten_level · 17,1162 posts'문어'지지마
@ozaoza06 · 1,0402 posts순대렐라의 바이오 하우스
@BIOWORLDJD · 4,0661 postMJ의 Bio & Healthcare
@BarbarianBHC · 4,9331 post조기주식회 공부방
@EarlyStock1 · 24,4021 post현업자의 맘대로 겜투일지
@Game2diarychannel · 5531 post오를주식 - 뉴스/경제/주식
@GoUpstock · 20,9701 post용사 힘멜이라면 이렇게 투자할테니까
@Himmel_Investment · 2051 post[IV Research]
@IVResearch · 2,4751 post일타강사 ’제약/바이오‘ 투자 길라잡이
@K_biopharma1st · 4,6031 post(사)바이오헬스케어협회
@bioha1228 · 2,7961 post바이오 & 주도주
@biokoreachannel · 1,0551 post1년에 1랩업
@fordouble · 2,7071 post기술적 분석으로 보는 주식시장 (by 소라게아빠)
@hermitcrab41_1 · 20,3741 post미국 주식 인사이더 🇺🇸 (US Stocks Insider)
@insidertracking · 71,9901 post지식 책꽂이 (이대호 기자)
@knowledge_to_wealth · 14,1701 post묻따방 🐕
@mootda · 19,6531 post나혼주
@nahonju · 2,1181 post너쟁이의 성실한 추추생활
@nje2e · 8,4781 post힙한 펭미업의 1인칭 시점
@pengmeup · 9,1391 post니체의 시간
@scdzito · 2,8711 post
Republishes
Channels on the register whose posts this channel has forwarded.
Republishes 82 registered channels. The 48 listed are the ones this channel has forwarded most; the rest are counted here but not each listed.
@darthacking · 65,07841 posts더파마 뉴스·인사이트| THE PHARMA
@BBAinsights · 1,09924 posts더바이오 뉴스룸
@thebio111 · 6,53215 posts알테오젠 IR
@alteogenIR · 9,79014 posts한경바이오인사이트
@hkbioinsight · 4,2848 posts묻따방 🐕
@mootda · 19,6538 postsemchina
@G2strategy · 147 postsYeouido Lab_여의도 톺아보기
@Yeouido_Lab · 43,2776 posts다올 의료기기/화장품 박종현
@alexppark · 8,5036 posts올릭스(주) - OliX Pharmaceuticals
@olix_official · 3,8006 posts에이프릴바이오 공식IR채널: 리레이팅 2026
@aprilbioipr · 4,4965 posts[신한 리서치본부] 화장품/의복
@shinhanconsumer · 1,7255 posts조기주식회 공부방
@EarlyStock1 · 24,4024 posts한양증권 제약/바이오 오병용
@bdragon0808 · 13,4144 posts바이오스펙테이터
@biospectatorT · 5,8734 posts습관이 부자를 만든다. 🧘
@habit4117 · 27,9304 posts허혜민의 제약/바이오 소식통
@huhpharm · 24,3084 posts미국 주식 인사이더 🇺🇸 (US Stocks Insider)
@insidertracking · 71,9904 posts알지노믹스 공식 IR/PR 채널
@rznomics · 1,1414 posts인벤티지랩 IR
@InventagelabIR · 1,1793 posts리가켐바이오 IR/PR 공식 채널
@SHIDGL · 10,0213 posts돼지바
@bbong_tta · 12,6923 posts상장기업 수사대 ☎️
@cyber_rangers · 16,9363 posts아이엠바이오로직스 IR/PR
@imbiologics_official · 5193 posts아스달 (IPO&스몰캡 달인)
@iposmallcap · 2,6073 posts이지스스트레티지 리서치
@jeilstock · 26,4083 posts요약하는 고잉
@one_going · 47,4003 postsBRILLER
@BRILLER_Research · 18,0722 posts지아이이노베이션 공식 IR
@GIInnovation · 2,0822 posts스마트앤그로스 (Smart & Growth)
@SmartnGrowth · 3,3042 postsablbio_official
@ablbio_official · 5,8132 posts[신한 리서치본부] 제약/바이오
@bio_shinhan · 21,4462 posts텐베거 인생을 위하여
@decapitaionforce · 8742 posts디앤디파마텍 공식 IR 채널
@dndpharmatech · 3,6332 postsPluto Research
@hedgehara · 19,0222 posts기술적 분석으로 보는 주식시장 (by 소라게아빠)
@hermitcrab41_1 · 20,3742 posts교보 음식료/화장품 권우정
@kyobofnbcosmetic · 5,8212 posts리브스메드
@livsmed · 8822 posts@오스코텍 IR/PR 공식 채널
@oscotecinc · 5862 posts[한투증권 투자전략 김대준]
@strategy_kis · 10,4272 postsYM리서치
@ym_research · 40,0712 posts[다올 매크로/투자전략] 조병현/박영찬/정현하/홍록은
@DaolMacro · 3,0491 postTIME ACT!VE ETF
@activeetf · 9,7001 postAWAKE - 마켓 브리핑
@awake_schedule · 17,2201 post(사)바이오헬스케어협회
@bioha1228 · 2,7961 post미래에셋 제약/바이오 김승민
@bioksm · 14,9621 post루팡
@bornlupin · 48,1991 postDAJU - 기업 공시
@daju_dart · 4,4471 post
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Mentions
Names
Channels on the register whose handles appear in this channel's posts.
@BBAinsights · 1,09923 posts올릭스(주) - OliX Pharmaceuticals
@olix_official · 3,8006 posts아이엠바이오로직스 IR/PR
@imbiologics_official · 5193 posts지아이이노베이션 공식 IR
@GIInnovation · 2,0822 postsBRILLER
@BRILLER_Research · 18,0721 post글로벌 바이오헬스케어 뉴스
@global_biohealthcare_news · 4,6081 post🧬바이오섹터 분석🧬 [그로쓰리서치]
@growthbio · 13,3571 postWalter Bloomberg
@WalterBloomberg · 32,4781 post미국 제약-바이오 주식/약장수
@yakjangsu · 11,4241 postYM리서치
@ym_research · 40,0711 post
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
Channels Telegram recommends alongside this one
Telegram’s own answer, not this register’s. When this register asks Telegram’s API what is similar to this channel, this is the list it returns, in the exact order Telegram returns it — never re-sorted by subscribers or by anything else this register measures. The relationship, and the order, are Telegram’s; we record them and date them, and make no claim of our own about which of these channels actually resemble this one.
@kimcharger · 24,931#1
@bdragon0808 · 13,414#2
@stocktrip · 7,286#3
@mstaryun · 18,703#4
@upper_limit_price · 8,000#5
@FastStockNews · 128,781#6
@allbareun · 12,221#7
@bumgore · 35,352#8
@bornlupin · 48,199#9
@survival_DoPB · 22,243#10
@Yeouido_Lab · 43,277#11
@bufkr · 22,185#12
@ym_research · 40,071#13
@gaoshoukorea · 41,159#14
@corevalue · 67,505#15
@twomachine · 5,305#16
@fastest_info1 · 13,317#17
@yakjangsu · 11,424#18
@psychotherapy101 · 5,958#19
@choaz1 · 7,068#20
@slsyphus · 4,401#21
@thesis_true · 2,324#22
@quantum_ALGO · 7,549#23
@cyber_rangers · 16,936#24
@awake_schedule · 17,220#25
@knowledge_to_wealth · 14,170#26
@huhpharm · 24,308#27
@EarlyStock1 · 24,402#28
@TambangVot · 8,598#29
@infomarketopen · 8,650#30
@stbridgee · 4,685#31
@jake8lee · 17,256#32
@ivy77788 · 5,952#33
@bioksm · 14,962#34
@shlrkQhqgla · 5,778#35
@daegurr · 23,375#36
@fourgachi · 8,384#37
@bbong_tta · 12,692#38
@yaza_stock · 13,070#39
@Ten_level · 17,116#40
@hermitcrab41_1 · 20,374#41
@awake_realtimeCheck · 22,632#42
@Onionfarmer · 15,975#43
@TRENDSETTERVERSION2 · 3,929#44
@desperatestudycafe · 18,751#45
@athletes_village · 21,621#46
@darthacking · 65,078#47
@stockinvcowcow · 13,942#48
@YeouidoStory2 · 58,411#49
@sunstudy1234 · 54,638#50
@tazastock · 40,440#51
@Fire_Direction_Center · 5,443#52
@bbanjil · 10,732#53
@easobi · 23,597#54
@orangeboard · 4,656#55
@investment_puzzle · 14,375#56
@growthresearch · 40,159#57
@aptvalueprice · 10,716#58
@insangnism · 11,282#59
@bumsong2 · 13,092#60
@mztanyong · 6,005#61
@Dogrini · 4,770#62
@ygamsung · 6,730#63
@getfeed · 8,783#64
@hanagae · 4,639#65
@stockgrandmaster · 10,920#66
@CTTResearch · 6,889#67
@small_stock · 8,990#68
@Kyaooo · 17,390#69
@pikachu_aje · 25,217#70
@anysong_Technon · 4,976#71
@cpshelter · 5,427#72
@nje2e · 8,478#73
@jeilstock · 26,408#74
@econostudy · 8,512#75
@Jstockclass · 26,067#76
@triple_stock · 12,956#77
@TNBfolio · 24,657#78
@infodart · 6,794#79
@selfstudystock · 3,719#80
@PRROEresearch · 4,630#81
@stockDaram2 · 5,122#82
@G2strategy · 14#83
@aetherjapanresearch · 34,509#84
@redbirdstock · 10,539#85
@seokokang · 6,191#86
@theelec · 10,811#87
@hwalja · 3,536#88
@tteoksangMalangCow · 69 (as read 7 September 2026)#89
Read from Telegram’s recommendation API, most recently 7 September 2026. Telegram holds a list like this for a small and growing share of the register — how this is measured, and why most channel pages show nothing here.
Appears in Telegram’s recommendations for other channels
The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.
@ym_research · 40,071
Telegram ranks this channel #4 of 89 here — alongside 88 others — read 2 September 2026
@corevalue · 67,505
Telegram ranks this channel #9 of 93 here — alongside 92 others — read 2 September 2026
@huhpharm · 24,308
Telegram ranks this channel #17 of 93 here — alongside 92 others — read 16 September 2026
@survival_DoPB · 22,243
Telegram ranks this channel #19 of 90 here — alongside 89 others — read 21 September 2026
@Yeouido_Lab · 43,277
Telegram ranks this channel #20 of 90 here — alongside 89 others — read 2 September 2026
@bornlupin · 48,199
Telegram ranks this channel #23 of 91 here — alongside 90 others — read 2 September 2026
@EarlyStock1 · 24,402
Telegram ranks this channel #25 of 91 here — alongside 90 others — read 16 September 2026
@kimcharger · 24,931
Telegram ranks this channel #25 of 88 here — alongside 87 others — read 15 September 2026
@gaoshoukorea · 41,159
Telegram ranks this channel #26 of 90 here — alongside 89 others — read 2 September 2026
@bumgore · 35,352
Telegram ranks this channel #30 of 89 here — alongside 88 others — read 2 September 2026
@bufkr · 22,185
Telegram ranks this channel #31 of 89 here — alongside 88 others — read 21 September 2026
@SmallCap · 23,176
Telegram ranks this channel #31 of 96 here — alongside 95 others — read 19 September 2026
@HS_academy · 36,164
Telegram ranks this channel #35 of 90 here — alongside 89 others — read 8 September 2026
@FastStockNews · 128,781
Telegram ranks this channel #36 of 92 here — alongside 91 others — read 2 September 2026
@HANAchina · 35,301
Telegram ranks this channel #43 of 92 here — alongside 91 others — read 2 September 2026
@pikachu_aje · 25,217
Telegram ranks this channel #44 of 91 here — alongside 90 others — read 14 September 2026
@jeilstock · 26,408
Telegram ranks this channel #46 of 93 here — alongside 92 others — read 12 September 2026
@darthacking · 65,078
Telegram ranks this channel #47 of 91 here — alongside 90 others — read 2 September 2026
@habit4117 · 27,930
Telegram ranks this channel #48 of 87 here — alongside 86 others — read 10 September 2026
@GoUpstock · 20,970
Telegram ranks this channel #49 of 83 here — alongside 82 others — read 25 September 2026
@sunstudy1234 · 54,638
Telegram ranks this channel #49 of 89 here — alongside 88 others — read 2 September 2026
@sypark_strategy · 29,465
Telegram ranks this channel #54 of 91 here — alongside 90 others — read 8 September 2026
@stock_messenger · 25,522
Telegram ranks this channel #58 of 90 here — alongside 89 others — read 14 September 2026
@awake_realtimeCheck · 22,632
Telegram ranks this channel #63 of 92 here — alongside 91 others — read 20 September 2026
This channel appears in 42 seed channels' Telegram-generated recommendation lists in total, of which the 24 where it ranks highest are shown above. Each is Telegram’s list for THAT channel, not this one — see how this is measured.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 26 September 2026 — this entry's latest reading, not the date you are reading this.
“제약/바이오/미용 원리버 Oneriver” (@pharmbiohana), 29,812 subscribers as measured 26 September 2026. Telegram Register, tgregister.com/channel/pharmbiohana.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.